Breast Cancer Mutations <i>HER2V777L</i> and <i>PIK3CAH1047R</i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Xiaoqing Cheng(Washington University in St. Louis), Ron Bose(University Hospitals Seidman Cancer Center)
Cited by 31
Related Papers
CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer
|Nature Genetics|2017|673
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
|The Lancet Oncology|2019|564
Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface
|Nature|2007|351
Analysis of the Role of the C-Terminal Tail in the Regulation of the Epidermal Growth Factor Receptor
|Molecular and Cellular Biology|2015|91
Quantitative Proteomics with siRNA Screening Identifies Novel Mechanisms of Trastuzumab Resistance in HER2 Amplified Breast Cancers
|Molecular & Cellular Proteomics|2012|47